These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 20368187)

  • 21. Effect of mergers and acquisitions on drug discovery: perspective from a case study of a Japanese pharmaceutical company.
    Shibayama S; Tanikawa K; Fujimoto R; Kimura H
    Drug Discov Today; 2008 Jan; 13(1-2):86-93. PubMed ID: 18190869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mergers and innovation in the pharmaceutical industry.
    Comanor WS; Scherer FM
    J Health Econ; 2013 Jan; 32(1):106-13. PubMed ID: 23220457
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Virtual pharmaceutical companies: collaborating flexibly in pharmaceutical development.
    Forster SP; Stegmaier J; Spycher R; Seeger S
    Drug Discov Today; 2014 Mar; 19(3):348-55. PubMed ID: 24291787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outcomes research: collaboration among academic researchers, managed care organizations, and pharmaceutical manufacturers.
    Kong SX; Wertheimer AI
    Am J Manag Care; 1998 Jan; 4(1):28-34. PubMed ID: 10179904
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The information revolution reaches pharmaceuticals: balancing innovation incentives, cost, and access in the post-genomics era.
    Rai AK
    Univ Ill Law Rev; 2001; 2001(1):173-210. PubMed ID: 16493845
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biomedical research and the pharmaceutical industry.
    Rosenfield G
    Pharos Alpha Omega Alpha Honor Med Soc; 1996; 59(3):46. PubMed ID: 9074323
    [No Abstract]   [Full Text] [Related]  

  • 28. An unbalanced portfolio.
    Federsel HJ
    Drug News Perspect; 2009 Jun; 22(5):287-92. PubMed ID: 19609466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brazil: An emerging partner in drug R&D.
    Rodrigues DG
    IDrugs; 2009 Aug; 12(8):497-502. PubMed ID: 19629884
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimizing the discovery organization for innovation.
    Sams-Dodd F
    Drug Discov Today; 2005 Aug; 10(15):1049-56. PubMed ID: 16055021
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New eyes on old drugs.
    Strauss S
    Nat Biotechnol; 2010 Jul; 28(7):633. PubMed ID: 20622811
    [No Abstract]   [Full Text] [Related]  

  • 32. Health research and innovation: Can we optimize the interface between startups/pharmaceutical companies and academic health care institutions or not?
    Dhainaut JF; Blin O; Herry F; ; Benito S; Bilbault P; Cauterman M; Favrel-Feuillade F; Fazi-Leblanc S; Germain C; Goehrs C; Grosskopf C; Labarthe B; Lechat P; Malciu C; Marquet P; Miceli-Richard C; Peyret O; Rattenbach R; de Saint-Exupéry E
    Therapie; 2020; 75(1):113-123. PubMed ID: 31948660
    [TBL] [Abstract][Full Text] [Related]  

  • 33. After slow start, project to channel drug company funds to universities builds steam.
    Berkowitz P
    CMAJ; 1996 Aug; 155(3):318-20. PubMed ID: 8705914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmaceutical technology management--profitable business avenue.
    Puthli SP
    Expert Opin Drug Deliv; 2010 Jan; 7(1):1-5. PubMed ID: 20017657
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Leveraging Industry-Academia Collaborations in Adaptive Biomedical Innovation.
    Stewart SR; Barone PW; Bellisario A; Cooney CL; Sharp PA; Sinskey AJ; Natesan S; Springs SL
    Clin Pharmacol Ther; 2016 Dec; 100(6):647-653. PubMed ID: 27617845
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of relational activities on HMO organizational outcomes.
    Doucette WR
    Am J Manag Care; 1999 Aug; 5(8):1025-34. PubMed ID: 10558126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration.
    Vitiello B; Heiligenstein JH; Riddle MA; Greenhill LL; Fegert JM
    Biol Psychiatry; 2004 Jul; 56(1):3-9. PubMed ID: 15219466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opening up to precompetitive collaboration.
    Altshuler JS; Balogh E; Barker AD; Eck SL; Friend SH; Ginsburg GS; Herbst RS; Nass SJ; Streeter CM; Wagner JA
    Sci Transl Med; 2010 Oct; 2(52):52cm26. PubMed ID: 20926831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Anticancer Drug Development: The Way Forward.
    Connors T
    Oncologist; 1996; 1(3):180-181. PubMed ID: 10387985
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The pharmaceutical industry and academic medicine in collaboration.
    Wroblewski R
    Circulation; 1985 Aug; 72(2 Pt 2):I3-7. PubMed ID: 4006154
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.